FDA restricts sale and distribution of Essure


Essure
April 9, 2018 Categories: Defective Medical Devices

Pin It

FDA restricts sale and distribution of Essure

As of today, FDA restricts sale and distribution of Essure to protect women and to require that patients receive risk information.

“The U.S. Food and Drug Administration today issued an order to restrict the sale and distribution of the Essure device to ensure that all women considering use of the permanent contraception device are provided with adequate risk information so that they can make informed decisions. The FDA is taking this step after becoming aware that some women were not being adequately informed of Essure’s risks before getting the device implanted, despite previous significant efforts to educate patients and doctors about the risks associated with this device.”

The U.S. Food and Drug Administration

Financial compensation may be available for individuals who have experienced serious complications after having an Essure procedure. Essure lawsuit cases are now able to proceed. Essure settlement offers will depend on the results of the first cases that make it to trial and each individual’s specific injuries.

Your Comment

Recent Updates

It has been a few years since Roundup®, a product of Monsanto, was reportedly linked to a serious disease called non-Hodgkin lymphoma. People who worked with the weed-killer Roundup® across the United States were exposed to glyphosate, which is the main ingredient in the most popular herbicide in the country. Case of DeWayne Johnson against...

July 25, 2018

The FDA issued a safety alert in December 2017, stating that some patients who received a gadolinium-based contrast during an MRI procedure, may retain the gadolinium in their bodies for months, or even for years, causing serious side effects. Gadolinium is commonly used in MRIs to enhance the images the test provides. Gadolinium is a...

July 18, 2018

Valsartan is mainly used for treatment of high blood pressure, congestive heart failure, and after a heart attack. The FDA has announced a recall of several drugs that contain the heart drug valsartan because a possible carcinogen NDMA (N-Nitrosodimethylamine) that was found in the recalled products. NDMA, which was found in the valsartan products, could...

July 17, 2018